Top-News
Dänemark

Strategic Partners AS Aktie

Aktie
WKN:  A3EYNB ISIN:  DK0062502894 US-Symbol:  OZYMF
118,50 €
-5,00 €
-4,05%
13.12.24
Handeln Depot/Watchlist
Aktienanzahl *
41,71 Mio.
Marktkapitalisierung *
5,32 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 26.11.2024

Strategic Partners AS News

18.05.22 - PLX
Orphazyme to Submit Restructuring Proposal Following Asset Sales Agreement with KemPharm
(PLX AI) – Orphazyme plans to present the proposal to Danish High Court and all known creditors and will be voted on at a meeting on 30 May. • Orphazyme: if restructuring proposal is ...
29.04.22 - PLX
Orphazyme Received Non-Binding Offers; Vast Majority of Proceeds Would Go to Creditors
(PLX AI) – Orphazyme has to date received certain non-​binding offers (the “Offers”) to purchase all of Orphazyme’s assets and operations. • Orphazyme vast majority of the consideration ...
22.03.22 - PLX
Orphazymes Withdraws EMA Application for Arimoclomol
(PLX AI) – Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-​Pick disease type C. • Receipt of the ...
23.02.22 - PLX
Orphazyme Says Arimoclomol Unlikely to Be Approved Next Month by EMA
(PLX AI) – Orphazyme notified by the CHMP of a negative trend vote on the MAA for arimoclomol in NPC. • The trend vote indicates that the CHMP's current orientation is to not approve ...
18.01.22 - PLX
Orphazyme Sees Smaller Operating Loss After Cutting Expenses
(PLX AI) – Orphazyme updates 2021 financial outlook. • Orphazyme 2021 Net revenue range narrowed to DKK 35 – 37 million from DKK 30-40 million • Orphazyme 2021 Operating ...
05.10.21 - PLX
Orphazyme Now Sees Higher Cash Reserves at End of 2021
(PLX AI) – Orphazyme now expects to end 2021 with a cash position of no less than DKK 80 million, up from about DKK 50 million guided previously. • The improved cash guidance ...
31.08.21 - PLX
Orphazyme H1 Net Loss Bigger Than Expected; Operating Loss Outlook Unchanged
(PLX AI) – Orphazyme half year net income DKK -463.8 million vs. estimate DKK -405 million. • Outlook FY operating loss DKK 670-700 million (unchanged) • Orphazyme recognized ...

Newssuche

Videos

newspaper
13.12.24
TRADING Insights Webinar vom 12.12.24
Themen: Aktienmarkt-​Entwicklung, Soft-​Commodities, wie Baumwolle, Kakao, Orangensaft, aber auch die ... Mehr »